open access

Vol 87, No 2 (2019)
REVIEWS
Published online: 2019-04-18
Submitted: 2019-01-15
Accepted: 2019-04-14
Get Citation

Cell-free tumour DNA as a diagnostic and prognostic biomarker in non-small cell lung carcinoma

Barbara Aleksandra Łochowska, Dariusz Nowak, Piotr Białasiewicz
DOI: 10.5603/ARM.2019.0019
·
Pubmed: 31038724
·
Adv Respir Med 2019;87(2):118-122.

open access

Vol 87, No 2 (2019)
REVIEWS
Published online: 2019-04-18
Submitted: 2019-01-15
Accepted: 2019-04-14

Abstract

More than 1 million people dies worldwide due to lung cancer which is the first most incident cancer in males and the third in females. Only early diagnosis makes possible to achieve long-lasting remission or even cure the disease. Unfortunately, no tumour marker to achieve this goal has been identified, yet. One of putative lung cancer markers is free circulating tumor DNA. Its concentration seems to be related to cancer burden. Moreover, it can be subjected to mutational status analysis allowing for introduction of targeted treatment. This led to the idea of liquid biopsy which can substitute for a standard biopsy not feasible in certain clinical circumstances. Assessment of cell free tumour DNA can also inform about progression/recurrence of cancer and may have a prognostic value. Therefore, the aim of this article is to review on free circulating DNA as a potential marker in lung cancer.

Abstract

More than 1 million people dies worldwide due to lung cancer which is the first most incident cancer in males and the third in females. Only early diagnosis makes possible to achieve long-lasting remission or even cure the disease. Unfortunately, no tumour marker to achieve this goal has been identified, yet. One of putative lung cancer markers is free circulating tumor DNA. Its concentration seems to be related to cancer burden. Moreover, it can be subjected to mutational status analysis allowing for introduction of targeted treatment. This led to the idea of liquid biopsy which can substitute for a standard biopsy not feasible in certain clinical circumstances. Assessment of cell free tumour DNA can also inform about progression/recurrence of cancer and may have a prognostic value. Therefore, the aim of this article is to review on free circulating DNA as a potential marker in lung cancer.

Get Citation

Keywords

free circulating DNA, liquid biopsy, lung cancer, biomarker

About this article
Title

Cell-free tumour DNA as a diagnostic and prognostic biomarker in non-small cell lung carcinoma

Journal

Advances in Respiratory Medicine

Issue

Vol 87, No 2 (2019)

Pages

118-122

Published online

2019-04-18

DOI

10.5603/ARM.2019.0019

Pubmed

31038724

Bibliographic record

Adv Respir Med 2019;87(2):118-122.

Keywords

free circulating DNA
liquid biopsy
lung cancer
biomarker

Authors

Barbara Aleksandra Łochowska
Dariusz Nowak
Piotr Białasiewicz

References (37)
  1. Didkowska J, Wojciechowska U, Mańczuk M, et al. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016; 4(8): 150.
  2. Tanoue LT, Tanner NT, Gould MK, et al. Lung cancer screening. Am J Respir Crit Care Med. 2015; 191(1): 19–33.
  3. Aberle DR, Adams AM, Berg CD, et al. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5): 395–409.
  4. Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9): 531–548.
  5. Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci. 2015; 16(6): 14122–14142.
  6. Jones HB. Some Account of a New Animal Substance Occurring in the Urine of a Patient Labouring under Mollities Ossium. Edinb Med Surg J. 1850; 74(185): 357–368.
  7. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37(3): 646–650.
  8. Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994; 3(1): 67–71.
  9. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61(4): 1659–1665.
  10. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003; 63(14): 3966–3968.
  11. Schwarzenbach H, Stoehlmacher J, Pantel K, et al. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci. 2008; 1137: 190–196.
  12. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32(6): 579–586.
  13. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224): 224ra24.
  14. Pathak AK, Bhutani M, Kumar S, et al. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 2006; 52(10): 1833–1842.
  15. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20(5): 548–554.
  16. Kordiak J, Szemraj J, Grabska-Kobylecka I, et al. Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate. J Cancer Res Clin Oncol. 2019; 145(1): 241–251.
  17. Remon J, Gorham J, Besse B, et al. Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Eur Respir J. 2015; 46(6): 1548–1550.
  18. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016; 2(8): 1014–1022.
  19. Zhuang R, Li S, Li Q, et al. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. PLoS One. 2017; 12(8): e0182562.
  20. Warton K, Samimi G. Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci. 2015; 2: 13.
  21. Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9(9): 1345–1353.
  22. Goss G, Tsai CM, Shepherd F, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology. 2016; 17(12): 1643–1652.
  23. Oxnard GR, Thress KS, Alden RS, et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(28): 3375–3382.
  24. Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017; 17(3): 209–215.
  25. Reck M, Hagiwara K, Han B, et al. ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. J Thorac Oncol. 2016; 11(10): 1682–1689.
  26. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004; 22(20): 4157–4164.
  27. Sozzi G, Roz L, Conte D, et al. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med. 2009; 179(1): 69–74.
  28. Dowler Nygaard A, Spindler KLG, Pallisgaard N, et al. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol Rep. 2014; 31(2): 969–974.
  29. Tissot C, Toffart AC, Villar S, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015; 46(6): 1773–1780.
  30. Kordiak J, Szemraj J, Hamara K, et al. Complete surgical resection of lung tumor decreases exhalation of mutated KRAS oncogene. Respir Med. 2012; 106(9): 1293–1300.
  31. Kumar S, Guleria R, Singh V, et al. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J. 2010; 36(4): 885–892.
  32. Li BT, Drilon A, Johnson ML, et al. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Ann Oncol. 2016; 27(1): 154–159.
  33. Wang S, Han X, Hu X, et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta. 2014; 430: 63–70.
  34. Cargnin S, Canonico PL, Genazzani AA, et al. Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2017; 12(1): 43–53.
  35. Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer. 2015; 113(3): 476–483.
  36. Szpechcinski A, Rudzinski P, Kupis W, et al. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer Lett. 2016; 374(2): 202–207.
  37. Leng S, Zheng J, Jin Y, et al. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis. Clin Chim Acta. 2018; 477: 160–165.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl